Key result
Stopping anticoagulation after AF ablation linked to fewer major hemorrhages with similarly low stroke rates.
Why the study?
AF increases thromboembolic risk and often requires oral anticoagulation therapy (OAT), and although pulmonary vein isolation is an effective treatment for AF, the safety of discontinuing OAT after apparently successful ablation required evaluation.
Does discontinuing oral anticoagulation therapy 3 to 6 months after successful atrial fibrillation ablation affect the risk of ischemic stroke and major hemorrhage compared to continuing oral anticoagulation therapy in patients with atrial fibrillation?
Cohort (n=3,355)
Yes
Does discontinuing oral anticoagulation therapy 3 to 6 months after successful atrial fibrillation ablation affect the risk of ischemic stroke and major hemorrhage compared to continuing oral anticoagulation therapy in patients with atrial fibrillation?
In this nonrandomized study, discontinuing oral anticoagulation 3 to 6 months after successful AF ablation was associated with a significantly lower rate of major hemorrhage without a statistically significant increase in ischemic stroke, even in patients with moderate-to-high thromboembolic risk.
Answers are grounded in this paper and cite their sources.
Risk after successful AF ablation remains uncertain; leaves open optimal anticoagulation duration pending prospective trials.
Objectives The aim of this multicenter study was to evaluate the safety of discontinuing oral anticoagulation therapy (OAT) after apparently successful pulmonary vein isolation. Background Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events (TE) and often requires OAT. Pulmonary vein isolation is considered an effective treatment for AF. Methods We studied 3,355 patients, of whom 2,692 (79% male, mean age 57 +/- 11 years) discontinued OAT 3 to 6 months after ablation (Off-OAT group) and 663 (70% male, mean age 59 +/- 11 years) remained on OAT after this period (On-OAT group). CHADS(2) (congestive heart failure, hypertension, age [75 years and older], diabetes mellitus, and a history of stroke or transient ischemic attack) risk scores of 1 and > or =2 were recorded in 723 (27%) and 347 (13%) Off-OAT group patients and in 261 (39%) and 247 (37%) On-OAT group patients, respectively. Results During follow-up (mean 28 +/- 13 months vs. 24 +/- 15 months), 2 (0.07%) Off-OAT group patients and 3 (0.45%) On-OAT group patients had an ischemic stroke (p = 0.06). No other thromboembolic events occurred. No Off-OAT group patient with a CHADS(2) risk score of > or =2 had an ischemic stroke. A major hemorrhage was observed in 1 (0.04%) Off-OAT group patient and 13 (2%) On-OAT group patients (p < 0.0001). Conclusions In this nonrandomized study, the risk-benefit ratio favored the suspension of OAT after successful AF ablation even in patients at moderate-high risk of TE. This conclusion needs to be confirmed by future large randomized trials.
No takes yet. Share an insight, caveat, or question.
Themistoclakis et al. (2010) conducted a cohort in Atrial fibrillation after successful pulmonary vein isolation (n=3,355). Discontinuation of oral anticoagulation therapy (Off-OAT) 3 to 6 months after ablation vs. Continuation of oral anticoagulation therapy (On-OAT) was evaluated on Ischemic stroke / thromboembolic events (p=0.06). Discontinuing oral anticoagulation 3-6 months after AF ablation yielded low ischemic stroke rates vs continuation and fewer major hemorrhages.
Synapse has enriched 10 related papers. Consider them for comparative context: